Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
  • C07D285/01—Five-membered rings
  • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
  • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
  • C07D285/01—Five-membered rings
  • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
  • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
  • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
  • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
  • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

• This invention relates to new propan-2-ol derivatives which have a strong selective effect on histamine-H 2 -receptors, to a process for their production and to medicaments containing these compounds and, finally, to the use of these compounds for therapeutic purposes.
• Cimetidine (Tagamet®) has already been used in the treatment of ulcers. Unfortunately, cimetidine has a relatively short half life. Because of this, tablets containing doses of 200 to 300 mg in a therapeutically established form have to be administered several times a day. Accordingly, there is a need for anti-ulcer agents which are more active and/or remain active for a longer period than cimetidine.
• the compounds obtainable in accordance with the invention inhibit the secretion of gastric acid when it is stimulated by histamine agonists [Ash and Schild, "Brit. J. Pharmacol. Chemother.”, 27, 427 (1966) and Black et al., “Nature”, 236, 385 (1971)].
• histamine agonists Ash and Schild, "Brit. J. Pharmacol. Chemother.”, 27, 427 (1966) and Black et al., "Nature”, 236, 385 (1971)].
• the pharmacological activity of these compounds which will be described in more detail hereinafter, may be demonstrated by a modified method according to DE-OS No. 27 34 070 in perfused rats' stomachs.
• the H 2 -antagonistic effect can be demonstrated on female Heidenhain-Pouch dogs using the method of Black et al., "Nature", 236, 385 (1971).
• the new compounds antagonize the effect of histamine on the frequency of contraction of the isolated right atrium of guinea pigs, but have no effect on histamine-induced contractions of the isolated, smooth gastrointestinal muscle where they are produced by H 2 -agonists.
• inhibitors for histamine-H 2 -receptors have an inhibiting effect both in regard to basal gastric acid secretion and also in regard to the secretion of gastric acid induced by gastrin, histamine, methacholine or food, they may be used in the treatment of peptic ulcers caused by the excessive secretion of gastric acid and also in the treatment of hyperacidic gastritis.
• the object of the present invention is to provide new inhibitors for histamine-H 2 -receptors which have an improved and/or longer lasting effect.
• the present invention relates to new propan-2-ol derivatives corresponding to the following general formula ##STR3## in which R represents ##STR4## and to salts thereof with pharmacologically acceptable acids.
• the salts are formed with suitable acids.
• suitable acids ar the hydrochlorides, hydrobromides, sulfates, methane sulfonates, acetates, maleates, succinates, citrates, tartrates, fumarates, benzoates, embonates, etc. and hydrates thereof.
• the invention also covers all tautomeric forms and all optically active isomers and salts thereof.
• the compounds according to the invention corresponding to formula (I) can form disalts which also fall within the scope of the invention.
• the compounds according to the invention are produced by a process which is characterized in that a compound corresponding to the following formula ##STR5## is reacted in known manner
• the reaction is carried out at a temperature from room temperature to the boiling temperature of the particular solvent and preferably at 25° C.
• Suitable solvents are, for example, alcohols, such as methanol, ethanol or isopropanol, preferably ethanol, or ethers, such as dioxane or tetrahydrofuran.
• the compound of general formula I obtained is separated off by standard methods, for example by chromatography or crystallization.
• the compound of general formula I obtained may be converted into its salts in known manner using a pharmacologically acceptable acid.
• the compounds according to the invention may be formulated in any way for administration. Accordingly, the invention also relates to medicaments containing at least one compound according to the invention for use in human or veterinary medicine.
• the medicaments according to the invention may be conventionally produced using one or more pharmaceutically compatible carriers or diluents.
• the compounds according to the invention may be formulated for oral, buccal, topical, parenteral or rectal administration, oral administration being preferred.
• the medicament may be present, for example, in the form of tablets, capsules, powders, solutions, syrups or suspensions which have been conventionally produced using acceptable diluents.
• the medicament may assume the form of tablets or capsules which have been conventionally formulated.
• the compounds according to the invention may be formulated for parenteral administration by bolus injection or continuous infusion.
• Formulations for injection may be present in unit dose form as ampoules or in multiple-dose containers with added preservative.
• the medicaments may assume such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulation aids, such as suspending agents, stabilizers and/or dispersants.
• formulation aids such as suspending agents, stabilizers and/or dispersants.
• the active principle may even be present in powder form for reconstitution before use with a suitable vehicle, for example sterile, pyrogen-free water.
• the compounds according to the invention may also be formulated for rectal preparations, for example suppositories or retention enemas containing, for example, conventional suppository bases, such as cocoa butter or other glycerides.
• the compounds according to the invention may be conventionally formulated as ointments, creams, gels, lotions, powders or sprays.
• a suitable daily dose of compounds according to the invention is from 1 to 4 doses containing a total of up to 5 mg to 1 g per day and preferably 5 to 250 mg per day, depending upon the condition of the patient.
• the compounds according to the invention are distinguished from recognized medicaments acting in the same direction by an improvement in the pharmacological activity levels. This is apparent from the results of the comparative pharmacological studies reported hereinafter.
• a recognized method of measuring H 2 -antagonistic activity is based on determination of the pA 2 -values in vitro on the isolated atrium of guinea pigs
• Rf 0.4 (Al 2 O 3 ; CH 2 Cl 2 ).
• HCl are added to the aqueous solution which is then filtered off under suction from the solid precipitated, after which the aqueous solution is adjusted to pH 12 with 2N NaOH and repeatedly extracted with acetic acid ethyl ester.
• This compound is produced as in Example 1 from 5.28 g (20 mMoles) of 1-amino-3-[3-(1-piperidinylmethyl)-phenoxy]-2-propanol and 3.4 g (20 mMoles) of 1,2-diethoxycyclobut-1-ene-3,4-dione.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=6204708

Family Applications (1)

Country Status (16)

Cited By (3)

Families Citing this family (1)

Citations (3)

Family Cites Families (4)

• 1983
  • 1983-07-22 DE DE19833326545 patent/DE3326545A1/de not_active Withdrawn
• 1984
  • 1984-05-30 EP EP84106217A patent/EP0132541A3/de not_active Withdrawn
  • 1984-06-13 DK DK290584A patent/DK290584A/da not_active Application Discontinuation
  • 1984-06-20 AU AU29536/84A patent/AU560038B2/en not_active Ceased
  • 1984-06-20 ZA ZA844651A patent/ZA844651B/xx unknown
  • 1984-06-21 IL IL72179A patent/IL72179A0/xx unknown
  • 1984-07-10 AR AR84297153A patent/AR242380A1/es active
  • 1984-07-11 KR KR1019840004048A patent/KR850001185A/ko not_active Application Discontinuation
  • 1984-07-16 US US06/630,963 patent/US4599346A/en not_active Expired - Fee Related
  • 1984-07-16 YU YU01230/84A patent/YU123084A/xx unknown
  • 1984-07-17 PT PT78923A patent/PT78923B/pt unknown
  • 1984-07-18 JP JP59150472A patent/JPS6042375A/ja active Pending
  • 1984-07-20 GR GR75380A patent/GR82256B/el unknown
  • 1984-07-20 HU HU842816A patent/HU192038B/hu unknown
  • 1984-07-20 ES ES534479A patent/ES8504160A1/es not_active Expired
  • 1984-07-20 NZ NZ208968A patent/NZ208968A/en unknown

Patent Citations (3)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events